NCM
CLRB icon

Nantahala Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Nantahala Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612K Buy
+219,998
New +$615K 0.02% 150
2024
Q4 		– Sell
-90,415
Closed -$5.8M – 138
2024
Q3 		$5.8M Buy
90,415
+29,304
+48% +$1.93M 0.29% 65
2024
Q2 		$4.58M Sell
61,111
-1,333
-2% -$128K 0.27% 66
2024
Q1 		$7.46M Buy
62,444
+17,425
+39% +$1.89M 0.43% 48
2023
Q4 		$3.74M Buy
+45,019
New +$3.35M 0.22% 76

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Nantahala Capital Management's CLRB Position: Q2 2026 in Review

Nantahala Capital Management opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 219,998 shares worth $612K. The stake represents 0.02% of the portfolio and ranks #150 among its holdings. This is a return to the name: Nantahala Capital Management previously reported a position in CLRB as recently as Q3 2024.

Nantahala Capital Management first reported a position in CLRB in Q4 2023 and has held it in 5 quarters since. The position peaked at $7.46M in Q1 2024. 29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Nantahala Capital Management held 219,998 shares of Cellectar Biosciences worth $612K as of Q2 2026.
  • Cellectar Biosciences was a new Nantahala Capital Management position in Q2 2026.
  • Cellectar Biosciences made up 0.02% of Nantahala Capital Management's portfolio in Q2 2026, its #150 holding.
  • Nantahala Capital Management first reported a position in Cellectar Biosciences in Q4 2023 and has held it in 5 quarters since.
  • Nantahala Capital Management's Cellectar Biosciences position peaked at $7.46M in Q1 2024.
  • 29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.